drugset
Drugs / donor-derived EBV-specific cytotoxic T-cells (EBV-CTL)
last change Nov 2015 re-read 3 minutes ago

donor-derived EBV-specific cytotoxic T-cells (EBV-CTL)

Cell therapy targets CD19

Developed for
acute lymphoblastic leukemia
Investigated by
Children with Leukaemia · Department of Health, United Kingdom · Deutsche Krebshilfe e.V., Bonn (Germany) · European Union · JP Moulton Charitable Foundation · The Leukemia and Lymphoma Society
+1 more · University College, London

Trials 1

today NCT01195480 · Ph 1/2
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT01195480 May 2012 → Nov 2015 acute lymphoblastic leukemia University College, London Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01195480 ↗
Modality Cell therapy “adoptive transfer of CD19ζ chimaeric receptor transduced donor-derived EBV-specific cytotoxic T-lymphocytes (EBV-CTL)” NCT01195480 ↗
Target CD19 “CD19-specific gene-engineered T cells” NCT01195480 ↗